Home Newsfeeds Keybanc Maintains Overweight on Smartsheet, Raises Price Target to $53

Keybanc Maintains Overweight on Smartsheet, Raises Price Target to $53

Keybanc analyst Jason Celino maintains Smartsheet (NYSE:SMAR) with a Overweight and raises the price target from $48 to $53.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Keybanc analyst Jason Celino maintains Smartsheet (NYSE:SMAR) with a Overweight and raises the price target from $48 to $53.

NVIDIA To Rally Over 67%? Here Are 10 Other Analyst Forecasts For Tuesday

By Lisa Levin

October 3, 8:07 AM

Keybanc raised the price target for NVIDIA Corporation (NASDAQ: NVDA) from $670 to $750. Keybanc analyst John Vinh maintained an Overweight rating. NVIDIA shares gained 3% to close at $447.82 on Monday.

CHPT

North Korea Says Situation Has Reached An Extreme Red-Line Due To Reckless Military Moves By U.S., Allies; Says U.S. Is Going To Ignite An All-Out Showdown With Its Military Drills; Says Will Take Toughest Reaction To Any U.S. Military Moves

By Michael Horton

February 1, 5:28 PM

-Reuters

EWY

How To Earn $500 A Month From Dole Stock Ahead Of Q1 Earnings Report

By Avi Kapoor

May 14, 8:54 AM

Dole plc (NYSE: DOLE) will release Q3 earnings before May 15. Analysts expect EPS of $0.31 and revenue of $2.12B. Annual dividend yield is 2.62%.

DOLE

First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results Expected 1H/2023

By Benzinga Newsdesk

December 1, 7:26 AM

First Wave BioPharma (NASDAQ:FWBI) reached a milestone that could quickly become a catalyst. And if that's the case, current share prices may present an investment opportunity too good to ignore. Why so bullish?

FWBI

Keybanc Maintains Overweight on Smartsheet, Raises Price Target to $53

Related Posts

NVIDIA To Rally Over 67%? Here Are 10 Other Analyst Forecasts For Tuesday

North Korea Says Situation Has Reached An Extreme Red-Line Due To Reckless Military Moves By U.S., Allies; Says U.S. Is Going To Ignite An All-Out Showdown With Its Military Drills; Says Will Take Toughest Reaction To Any U.S. Military Moves

How To Earn $500 A Month From Dole Stock Ahead Of Q1 Earnings Report

First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results Expected 1H/2023